{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+10+mg&page=2",
    "query": {
      "intervention": "Empagliflozin 10 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+10+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+10+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T16:20:08.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06110130",
      "title": "Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington D.C. Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-02-02",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06110130"
    },
    {
      "nct_id": "NCT05726032",
      "title": "Empagliflozin in Patients With Cirrhosis and Ascites",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Liver Failure"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-09-11",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05726032"
    },
    {
      "nct_id": "NCT06843902",
      "title": "Improving Coronary Vascular Health in Women",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection",
        "Coronary Microvascular Dysfunction",
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Health Education",
          "type": "OTHER"
        },
        {
          "name": "Subspecialty clinic referral",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 75 Years · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2025-04-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06843902"
    },
    {
      "nct_id": "NCT03448419",
      "title": "This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2018-03-20",
      "completion_date": "2019-10-07",
      "has_results": true,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 41,
      "location_summary": "Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03448419"
    },
    {
      "nct_id": "NCT04027023",
      "title": "Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Diabetes mellitus Type 2 De-escalation treatment (DET)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sciema UG",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-10-30",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04027023"
    },
    {
      "nct_id": "NCT06201000",
      "title": "Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Genetic Polymorphisms",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitors (Dapagliflozin and Empagliflozin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "October 6 University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 282,
      "start_date": "2023-12-27",
      "completion_date": "2024-09-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06201000"
    },
    {
      "nct_id": "NCT07756294",
      "title": "Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-11",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756294"
    },
    {
      "nct_id": "NCT07155694",
      "title": "Role of Finerenone in African American Veterans With Diabetic Kidney Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Finerenone 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington D.C. Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "20 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-01",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07155694"
    },
    {
      "nct_id": "NCT05786443",
      "title": "Safety and Efficacy of Empagliflozin in Hemodialysis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-31",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05786443"
    },
    {
      "nct_id": "NCT05553938",
      "title": "Effects of Acute and Chronic Empagliflozin Heart Failure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-08-04",
      "completion_date": "2026-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-03T16:20:08.182Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05553938"
    }
  ]
}